ROSEN, LEADING INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - ALDX

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Aldeyra Therapeutics, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Company Information - Aldeyra Therapeutics, Inc. received a Complete Response Letter from the U.S. Food and Drug Administration regarding its New Drug Application for reproxalap, indicating a lack of substantial evidence for the drug's efficacy in treating dry eye disease [3]. - Following the announcement of the Complete Response Letter, Aldeyra's stock price fell by $2.99 per share, representing a 70.7% decline, closing at $1.24 per share on March 17, 2026 [3]. Group 2: Legal Actions - Investors who purchased Aldeyra securities may be entitled to compensation through a class action lawsuit, with no out-of-pocket fees or costs due to a contingency fee arrangement [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to the misleading information [2]. Group 3: Rosen Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and being recognized for its success in the field [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].